Alternative performance measures
This report contains financial key figures in accordance with the frameworks applied by AddLife, which are based on IFRS. In addition, there are alternative performance measures (APM) that cannot be directly extracted or derived from the financial statements. These key figures are essential for understanding and evaluating AddLife's operations and financial position. They should not be seen as a replacement for the measures defined according to IFRS but rather as a complement to the financial reporting. Since not all companies calculate financial measures in the same way, these are not always comparable with measures used by other companies. The key figures are presented below and commented on in other parts of .
Return on equity
| Sep 30 | Sep 30 | Full year | |
| SEKm | 2026 | 2025 | 2025 |
| Profit/loss for the period attributable to shareholders (rolling 12 months) | 644 | 394 | 560 |
| Average equity | 5,612 | 5,232 | 5,293 |
| Return on equity, % | 11 | 8 | 11 |
Return on working capital (P/WC)
| Sep 30 | Sep 30 | Full year | |
| SEKm | 2026 | 2025 | 2025 |
| EBITA (rolling 12 months) | 1,501 | 1,266 | 1,417 |
| Inventories, average | 1,771 | 1,746 | 1,713 |
| Accounts receivable, average | 1,613 | 1,579 | 1,586 |
| Accounts payable, average | -1,005 | -1,016 | -1,013 |
| Working capital, average | 2,379 | 2,309 | 2,286 |
| Return on working capital, % | 63 | 55 | 62 |
EBITA and EBITDA
| Q3 | Q3 | Jan-Sep | Jan-Sep | Oct 2025- | Full year | |
| SEKm | 2026 | 2025 | 2026 | 2025 | Sep 2026 | 2025 |
| Operating profit | 221 | 165 | 686 | 600 | 1,079 | 993 |
| Amortisation and impairment of intangible assets | 109 | 105 | 318 | 320 | 422 | 424 |
| EBITA | 330 | 270 | 1,004 | 920 | 1,501 | 1,417 |
| Depreciation and impairment of tangible assets | 101 | 94 | 287 | 280 | 392 | 385 |
| EBITDA | 431 | 364 | 1,291 | 1,200 | 1,893 | 1,802 |
Adjusted EBITA
| Q3 | Q3 | Jan-Sep | Jan-Sep | Oct 2025- | Full year | |
| SEKm | 2026 | 2025 | 2026 | 2025 | Sep 2026 | 2025 |
| EBITA | 330 | 270 | 1,004 | 920 | 1,501 | 1,417 |
| One-off costs | ||||||
| Sale of business | – | – | – | – | -158 | -158 |
| Revalued contingent consideration | -32 | – | -32 | – | -32 | – |
| Adjusted EBITA | 298 | 270 | 972 | 920 | 1,311 | 1,259 |
EBITA margin / Adjusted EBITA margin
| Q3 | Q3 | Jan-Sep | Jan-Sep | Oct 2025- | Full year | |
| SEKm | 2026 | 2025 | 2026 | 2025 | Sep 2026 | 2025 |
| EBITA | 330 | 270 | 1,004 | 920 | 1,501 | 1,417 |
| Net sales | 2,599 | 2,429 | 7,965 | 7,709 | 10,698 | 10,442 |
| EBITA margin, % | 12.7 | 11.1 | 12.6 | 11.9 | 14.0 | 13.6 |
| Adjusted EBITA | 298 | 270 | 972 | 920 | 1,311 | 1,259 |
| Adjusted EBITA margin, % | 11.5 | 11.1 | 12.2 | 11.9 | 12.3 | 12.1 |
Organic growth
| Labtech | Medtech | The Group¹ | ||||||
| Q3 | Q3 | Q3 | Q3 | Q3 | Q3 | |||
| % | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | ||
| Total growth | 8.5 | 6.3 | 6.0 | 2.1 | 7.0 | 3.6 | ||
| (-) Currency effect | 1.1 | -2.4 | 1.0 | -3.3 | 1.0 | -3.0 | ||
| (-) Acquired growth | 5.5 | – | 1.4 | 1.5 | 2.9 | 1.0 | ||
| Organic growth | 1.9 | 8.7 | 3.6 | 3.9 | 3.1 | 5.6 | ||
| | ||||||||
| Labtech | Medtech | The Group¹ | ||||||
| Q3 | Q3 | Q3 | Q3 | Q3 | Q3 | |||
| SEKm | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | ||
| Total growth | 77 | 54 | 93 | 30 | 170 | 85 | ||
| (-) Currency effect | 10 | -20 | 17 | -50 | 24 | -69 | ||
| (-) Acquired growth | 50 | – | 21 | 22 | 71 | 22 | ||
| Organic growth | 17 | 74 | 55 | 58 | 75 | 132 | ||
| Labtech | Medtech | The Group¹ | ||||||
| Jan-Sep | Jan-Sep | Jan-Sep | Jan-Sep | Jan-Sep | Jan-Sep | |||
| % | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | ||
| Total growth | 5.0 | 8.4 | 2.3 | 0.3 | 3.3 | 3.2 | ||
| (-) Currency effect | -0.7 | -2.5 | -1.4 | -2.6 | -1.2 | -2.5 | ||
| (-) Acquired growth | 3.5 | 1.9 | 1.7 | 1.0 | 2.4 | 1.3 | ||
| Organic growth | 2.2 | 9.0 | 2.0 | 1.9 | 2.1 | 4.4 | ||
| | ||||||||
| Labtech | Medtech | The Group¹ | ||||||
| Jan-Sep | Jan-Sep | Jan-Sep | Jan-Sep | Jan-Sep | Jan-Sep | |||
| SEKm | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | ||
| Total growth | 145 | 224 | 112 | 15 | 256 | 241 | ||
| (-) Currency effect | -20 | -65 | -68 | -122 | -89 | -186 | ||
| (-) Acquired growth | 102 | 51 | 83 | 47 | 185 | 98 | ||
| Organic growth | 63 | 238 | 97 | 90 | 160 | 329 | ||
| ¹The Group includes eliminations | ||||||||
Profit growth EBITA / Profit growth adjusted EBITA
| Sep 30 | Sep 30 | Full year | |
| SEKm | 2026 | 2025 | 2025 |
| EBITA (rolling 12 months) | 1,501 | 1,266 | 1,417 |
| (-) Previous year's EBITA (rolling 12 months) | 1,266 | 1,091 | 1,159 |
| EBITA growth | 235 | 175 | 258 |
| Profit growth EBITA, % | 19 | 16 | 22 |
| | |||
| Adjusted EBITA (rolling 12 months) | 1,311 | 1,266 | 1,259 |
| (-) Previous year's adjusted EBITA (rolling 12 months) | 1,266 | 1,077 | 1,165 |
| Adjusted EBITA growth | 45 | 189 | 94 |
| Profit growth adjusted EBITA, % | 4 | 18 | 8 |
Financial net liabilities and Net debt/equity ratio
| Sep 30 | Sep 30 | Full year | |
| SEKm | 2026 | 2025 | 2025 |
| Borrowing | 4,343 | 4,407 | 4,146 |
| Cash and cash equivalents | -477 | -286 | -813 |
| Financial net debt | 3,866 | 4,121 | 3,333 |
| Pension liability | 57 | 61 | 58 |
| Lease liability | 571 | 503 | 504 |
| Contingent considerations | 225 | 106 | 124 |
| Provisions | 27 | 30 | 29 |
| Net interest-bearing debt | 4,746 | 4,821 | 4,048 |
| Total equity | 5,958 | 5,308 | 5,447 |
| Net debt/equity ratio, multiple | 0.8 | 0.9 | 0.7 |
Financial net liabilities/EBlTDA
| Sep 30 | Sep 30 | Full year | |
| SEKm | 2026 | 2025 | 2025 |
| Net interest-bearing debt | 4,746 | 4,821 | 4,048 |
| EBITDA (rolling 12 months) | 1,893 | 1,644 | 1,802 |
| Financial net liabilities/EBITDA, multiple | 2.5 | 2.9 | 2.2 |
Equity ratio
| Sep 30 | Sep 30 | Full year | |
| SEKm | 2026 | 2025 | 2025 |
| Total equity | 5,958 | 5,308 | 5,447 |
| Total assets | 13,625 | 12,660 | 12,711 |
| Equity ratio, % | 44 | 42 | 43 |